Search Clinical Trials
Terminated
Bone Marrow Transplant From Related Donor for Patients With High Risk Hemoglobinopathies (External Link)
To do the bone marrow transplant, we must first kill the cells in the bone marrow that make the abnormal red blood cells that are found in patients with severe …
Baylor Role:
Lead Sponsor
Completed
Evaluating the Use of RFT5-dgA to Deplete Alloreactive Cells Prior to Haploidentical Stem Cell Transplantation (External Link)
Patients will receive cytosine arabinoside (3g/m^2) IV every 12 hours for 6 doses starting at 1400 hours on day -8. Cyclophosphamide (45mg/kg) will be given on Day -7 and Day …
Baylor Role:
Lead Sponsor
Completed
Study of Systemic and Spinal Chemotherapy Followed by Radiation for Infants With Brain Tumors (External Link)
All children in the study will receive Regimen 1 chemotherapy. Children whose tumor is limited to one area at the beginning of the study will go on to have radiation …
Baylor Role:
Lead Sponsor
Completed
T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts (External Link)
To participate in this study, the subject will need to have a central line (a thin plastic catheter or tube that is placed during surgery into one of the large …
Baylor Role:
Lead Sponsor
Completed
Stem Cell Transplant to Treat Patients With Systemic Sclerosis (External Link)
Before the transplant the research participant will receive daily G-CSF (Neupogen) for 5-6 days. This medication will help to stimulate the production of white blood cells (WBC) that will be …
Baylor Role:
Lead Sponsor
Completed
High Dose Chemo/Radiotherapy and Hematopoietic Stem Cell Transplant for Patients With Multiple Sclerosis (External Link)
To participate in this study, patients will need to have a central line (a thin plastic catheter or tube that is placed during surgery into one of the large veins …
Baylor Role:
Lead Sponsor
Completed
Intrathecal Mafosfamide (External Link)
Mafosfamide is given directly into the cerebrospinal fluid twice a week for six successive weeks. If after six weeks the disease has not shown any evidence of progression (tumor growth) …
Baylor Role:
Lead Sponsor